InZuanic & Associates' latest equity report, senior analystPablo ZuanicanalyzesMariMed's (OTC:MRMD) performance across its core markets, with Illinois (IL) accounting for 40-45% of the company's sales.

Despite overall market stagnation, MariMed aims to boost growth through capacity expansion, including a new 14,000 sq ft cultivation site expected to begin sales by early 2025.

• Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can't afford to miss out if you're serious about the business.

Q3

In Q3, Illinois' cannabis sales reached...